Biomx

Biomx P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Biomx (PHGE) as of Oct 23, 2026 is -0.37. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -0.26 — a change of 40.13% (lower).

P/CF

-0.37

YoY

40.13%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Biomx is 2025 -0.37 . P/CF (Price-to-Cash-Flow Ratio) of Biomx was 2024 -0.26 . It decreases by 40.13% lower compared to the previous year.

The Biomx P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-325,608.43 USD
Jan 1, 2019
-0.56 USD
Jan 1, 2020
-0.40 USD
Jan 1, 2021
-0.35 USD
Jan 1, 2022
-0.34 USD
Jan 1, 2023
-0.46 USD
Jan 1, 2024
-0.26 USD
Jan 1, 2025
-0.37 USD
The Biomx P/CF history
YEARP/CFYoY
-0.37+40.13%
-0.26-42.44%
-0.46+36.67%
-0.34-5.22%
-0.35-11.34%
-0.40-28.10%
-0.56-100.00%
-325,608.43+13.67 M%
-2.38-67.41%
-7.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomx Stock analysis

What does Biomx do? BiomX Ltd develops bacteriophage-based therapies targeting dysbiosis-related diseases, focusing on natural and engineered phage solutions. The company's pipeline includes BX001 for acne-prone skin, BX002 for IBD bacterial targets, and BX003 for Klebsiella pneumoniae strains. BiomX discovers and validates bacterial targets to customize phage compositions, aiming to treat conditions like inflammatory bowel disease, primary sclerosing cholangitis, and cancer through targeted bacterial destruction. The firm creates therapies for skin appearance issues and chronic diseases, with BX001 addressing acne, BX002 targeting IBD onset bacteria, and BX003 focusing on specific Klebsiella pneumoniae strains. BiomX's approach involves developing both natural and engineered phage cocktails tailored to bacterial targets, ensuring precise treatment for microbiome-related conditions without naming specific buyers or segments. BiomX Ltd's revenue model relies on the development and commercialization of its phage therapy pipeline. The company's products BX001, BX002, and BX003 are designed to treat specific bacterial-related conditions, with BX001 targeting skin appearance, BX002 for IBD, and BX003 for Klebsiella pneumoniae, all developed through customized phage compositions against validated bacterial targets. Biomx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomx stock

P/CF (Price-to-Cash-Flow Ratio) of Biomx is -0.37 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Biomx changed from -0.26 to -0.37, representing a 40.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Biomx since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Biomx with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biomx

All Key Metrics — Biomx